Lipocine Inc.

Quick facts

Phase 3 pipeline

• LPCN 1021 · Endocrinology
  LPCN 1021 is a novel oral androgen receptor agonist designed to deliver testosterone systemically for hormone replacement therapy.
• LPCN 1154A · Endocrinology
  LPCN 1154A is a novel oral androgen receptor modulator that selectively activates androgen signaling in target tissues.
• Oral testosterone undecanoate, LPCN 1021 · Endocrinology
  Oral testosterone undecanoate replaces deficient testosterone by providing exogenous androgen that binds to androgen receptors throughout the body.
• Topical testosterone gel 1.62 % · Hormone Replacement Therapy
  Topical testosterone gel 1.62% works by delivering testosterone through the skin to increase androgen levels in the body.

Phase 2 pipeline

• LPCN 1144
• LPCN 1144 Formulation A
• LPCN 1144 Formulation B · Urology
  LPCN 1144 Formulation B is a testosterone replacement therapy.
• LPCN 1148

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Lipocine Inc. portfolio CI brief
• Lipocine Inc. pipeline updates RSS